Statistics

Total Visits

Views
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)83

Select a period of time:

Number of views in the range

Views
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)42

Views

Views
June 20251
July 202521
August 20253
September 20256
October 20253
November 20254
December 20254
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States16
Brazil14
United Kingdom3
Venezuela2
Egypt2
Argentina1
Austria1
Colombia1
France1
Hong Kong1
 

Top cities views

Views
Giza2
Ashburn1
Belém1
Bragança Paulista1
Carlinville1
Chicago1
Contendas do Sincorá1
Cúa1
Dallas1
Hong Kong1